SCHEMBL4741908

SCHEMBL4741908

COc1ccc2cc(N(C)Cc3ccc(N(C)C)cc3)c(-c3cccnc3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.51
RAD51 Q06609 2/20 0.48
CYP11B2 P19099 9/20 0.46
CYP11B1 P15538 9/20 0.46
CYP17A1 P05093 4/20 0.46
CYP19A1 P11511 2/20 0.46
CYP2C9 P11712 1/20 0.45
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GBA1 P04062 1/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.40
PDK1 Q15118 1/20 0.40
APP P05067 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741913 0.80 GPBAR1 (0.68) GPBAR1RAD51CYP11B2CYP11B1CYP17A1
SCHEMBL4743145 0.67 GPBAR1 (0.66) GPBAR1RAD51CYP11B2CYP11B1CYP17A1
SCHEMBL4741378 0.67 GPBAR1 (1.00) GPBAR1
SCHEMBL4879950 0.67 GPBAR1 (0.83) GPBAR1CYP11B2CYP11B1CYP19A1CYP2C9
SCHEMBL4741853 0.67 GPBAR1 (0.83) GPBAR1CYP11B2CYP11B1CYP17A1CYP19A1
SCHEMBL4742051 0.67 GPBAR1 (0.66) GPBAR1RAD51CYP11B2CYP11B1CYP19A1
SCHEMBL10690882 0.66 ALDH1A1 (0.63) RAD51CYP2C9NPC1RAB9AMAPT
SCHEMBL20816328 0.66 RAD51 (1.00) RAD51CYP11B2CYP11B1CYP17A1CYP19A1
SCHEMBL10689435 0.65 RAD51 (0.61) RAD51CYP2C9NPC1RAB9AMAPT
SCHEMBL29469449 0.65 KMT2A (0.53) ALDH1A1PDK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPR119, GPBAR1, LDLR GPBAR1 2/4885RAD51 4838/4885CYP11B2 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.